From GlobeNewswire: 2025-06-04 11:32:00

Alvotech (NASDAQ: ALVO) plans to conduct a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares through an accelerated bookbuilding process. The Placement will be directed to Swedish and international institutional investors and is expected to raise funds for accelerating R&D activities and general corporate purposes. The price and total number of SDRs and shares offered will be determined through a bookbuilding procedure conducted by DNB Carnegie, Citi, SEB, and ACRO. The completion of the Placement is expected before trading commences on Nasdaq Stockholm on June 5, 2025.

The Placement aims to broaden Alvotech’s shareholder base with institutional investors, particularly in Sweden, where the Company recently listed SDRs on Nasdaq Stockholm. The funds raised will support the acceleration of R&D activities, especially after the acquisition of the R&D operations of Xbrane. Investors can acquire SDRs listed on Nasdaq Stockholm or ordinary shares listed on Nasdaq Iceland. The subscription price will be determined through the bookbuilding process and reflect prevailing market conditions and investor demand.

Alvotech has appointed DNB Carnegie, Citi, SEB, and ACRO as Joint Global Coordinators and Joint Bookrunners for the Placement. The Company’s Board of Directors and executive management have agreed to lock-up undertakings, restricting the sale or transfer of additional SDRs, ordinary shares, or other securities for a specified period. Shareholders Aztiq Pharma Partners S.à r.l., Alvogen Lux Holdings S.à r.l., and Celtic Holdings II Limited have also committed to similar lock-up arrangements.



Read more at GlobeNewswire: Alvotech intends to carry out a private placement of